A case study ‘APA’ research paper on: ‘Uber Collides with Controversy’ 10 pages We are using business ethics textbook for the class on ‘Cengage’

APA Research Paper (Mirano)

Source: Diana Hacker (Boston: Bedford/St. Martin’s, 2006). This paper follows the style guidelines in the Publication Manual of the American Psychological Association, 6th ed. (2010).

Obesity in Children i

Can Medication Cure Obesity in Children?

A Review of the Literature

Luisa Mirano

Psychology 107, Section B

Professor Kang

October 31, 2004

Short title and page number for student papers.

Full title.

XXXX

Marginal annotations indicate APA-style formatting and effective writing.

Obesity in Children 1

Writer’s name, course, section number, instructor’s name, and date (all centered).

Source: Diana Hacker (Boston: Bedford/St. Martin’s, 2006).

Abstract appears on a separate page.

Obesity in Children 2

Abstract

In recent years, policymakers and medical experts have

expressed alarm about the growing problem of childhood obesity

in the United States. While most agree that the issue deserves

attention, consensus dissolves around how to respond to the

problem. This literature review examines one approach to treating

childhood obesity: medication. The paper compares the

effectiveness for adolescents of the only two drugs approved by

the Food and Drug Administration (FDA) for longterm treatment

of obesity, sibutramine and orlistat. This examination of

pharmacological treatments for obesity points out the limitations

of medication and suggests the need for a comprehensive solution

that combines medical, social, behavioral, and political approaches

to this complex problem.

Source: Diana Hacker (Boston: Bedford/St. Martin’s, 2006).

Full title, centered.

The writer uses a footnote to define an essential term that would be cum- bersome to define within the text.

The writer sets up her organiza- tion by posing four questions.

The writer states her thesis.

Obesity in Children 3

Can Medication Cure Obesity in Children?

A Review of the Literature

In March 2004, U.S. Surgeon General Richard Carmona

called attention to a health problem in the United States that,

until recently, has been overlooked: childhood obesity. Carmona

said that the “astounding” 15% child obesity rate constitutes

an “epidemic.” Since the early 1980s, that rate has “doubled in

children and tripled in adolescents.” Now more than nine million

children are classified as obese.1 While the traditional response

to a medical epidemic is to hunt for a vaccine or a cure-all pill,

childhood obesity has proven more elusive. The lack of success

of recent initiatives suggests that medication might not be the

answer for the escalating problem. This literature review considers

whether the use of medication is a promising approach for solving

the childhood obesity problem by responding to the following

questions:

1. What are the implications of childhood obesity?

2. Is medication effective at treating childhood obesity?

3. Is medication safe for children?

4. Is medication the best solution?

Understanding the limitations of medical treatments for

children highlights the complexity of the childhood obesity

problem in the United States and underscores the need for

1Obesity is measured in terms of body-mass index (BMI): weight in kilograms divided by square of height in meters. A child or an adolescent with a BMI in the 95th percentile for his or her age and gender is considered obese.

Source: Diana Hacker (Boston: Bedford/St. Martin’s, 2006).

Headings, centered, help readers follow the organization.

In a signal phrase, the word “and” links the names of two authors; the date is given in parentheses.

Because the author (Carmona) is not named in the signal phrase, his name and the date appear in parentheses.

Obesity in Children 4

physicians, advocacy groups, and policymakers to search for

other solutions.

What Are the Implications of Childhood Obesity?

Obesity can be a devastating problem from both an

individual and a societal perspective. Obesity puts children at risk

for a number of medical complications, including type 2 diabetes,

hypertension, sleep apnea, and orthopedic problems (Henry J.

Kaiser Family Foundation, 2004, p. 1). Researchers Hoppin and

Taveras (2004) have noted that obesity is often associated with

psychological issues such as depression, anxiety, and binge eating

(Table 4).

Obesity also poses serious problems for a society

struggling to cope with rising health care costs. The cost of

treating obesity currently totals $117 billion per year—a price,

according to the surgeon general, “second only to the cost of

[treating] tobacco use” (Carmona, 2004). And as the number of

children who suffer from obesity grows, long-term costs will

only increase.

Is Medication Effective at Treating Childhood Obesity?

The widening scope of the obesity problem has prompted

medical professionals to rethink old conceptions of the disorder

and its causes. As researchers Yanovski and Yanovski (2002) have

explained, obesity was once considered “either a moral failing or

evidence of underlying psychopathology” (p. 592). But this view

has shifted: Many medical professionals now consider obesity a

biomedical rather than a moral condition, influenced by both

genetic and environmental factors. Yanovski and Yanovski have

Source: Diana Hacker (Boston: Bedford/St. Martin’s, 2006).

Ellipsis mark indicates omitted words.

An ampersand links the names of two authors in parentheses.

The writer draws attention to an important article.

Obesity in Children 5

further noted that the development of weight-loss medications in

the early 1990s showed that “obesity should be treated in the

same manner as any other chronic disease . . . through the

long-term use of medication” (p. 592).

The search for the right long-term medication has been

complicated. Many of the drugs authorized by the Food and

Drug Administration (FDA) in the early 1990s proved to be a

disappointment. Two of the medications—fenfluramine and

dexfenfluramine—were withdrawn from the market because of

severe side effects (Yanovski & Yanovski, 2002, p. 592), and

several others were classified by the Drug Enforcement

Administration as having the “potential for abuse” (Hoppin &

Taveras, 2004, Weight-Loss Drugs section, para. 6). Currently only

two medications have been approved by the FDA for long-term

treatment of obesity: sibutramine (marketed as Meridia) and

orlistat (marketed as Xenical). This section compares studies on

the effectiveness of each.

Sibutramine suppresses appetite by blocking the reuptake

of the neurotransmitters serotonin and norepinephrine in the

brain. Though the drug won FDA approval in 1998, experiments

to test its effectiveness for younger patients came considerably

later. In 2003, University of Pennsylvania researchers

Berkowitz, Wadden, Tershakovec, and Cronquist released the

first double-blind placebo study testing the effect of sibutramine

on adolescents, aged 13-17, over a 12-month period. Their

findings are summarized in Table 1.

After 6 mos.: loss of 3.2 kg (7 lb)

After 12 mos.: loss of 4.5 kg (9.9 lb)

After 6 mos.: loss of 7.8 kg (17.2 lb)

After 12 mos.: loss of 7.0 kg (15.4 lb)

Gain of 0.67 kg (1.5 lb)

Loss of 1.3 kg (2.9 lb)

Table 1

Effectiveness of Sibutramine and Orlistat in Adolescents Average weight

Medication Subjects Treatmenta Side effects loss/gain

Sibutramine

Orlistat

Control

Medicated

Control

Medicated

0-6 mos.: placebo

6-12 mos.: sibutramine

0-12 mos.: sibutramine

0-12 mos.: placebo

0-12 mos.: orlistat

Mos. 6-12: increased blood pressure; increased pulse rate

Increased blood pressure; increased pulse rate

None

Oily spotting; flatulence; abdominal discomfort

Source: Diana Hacker (Boston: Bedford/St. Martin’s, 2006).

The writer uses a table to summa- rize the findings presented in two sources.

A note gives the source of the data.

A content note explains data common to all subjects.

Note. The data on sibutramine are adapted from “Behavior Therapy and

Sibutramine for the Treatment of Adolescent Obesity,” by R. I. Berkowitz,

T. A. Wadden, A. M. Tershakovec, & J. L. Cronquist, 2003, Journal of

the American Medical Association, 289, pp. 1807-1809. The data on

orlistat are adapted from Xenical (Orlistat) Capsules: Complete Product

Information, by Roche Laboratories, December 2003, retrieved from

http://www.rocheusa.com/products/xenical/pi.pdf

aThe medication and/or placebo were combined with behavioral therapy

in all groups over all time periods.

Obesity in Children 6

Source: Diana Hacker (Boston: Bedford/St. Martin’s, 2006).

When this article was first cited, all four authors were named. In subse- quent citations of a work with three to five authors, “et al.” is used after the first author’s name.

Obesity in Children 7

After 6 months, the group receiving medication had lost

4.6 kg (about 10 pounds) more than the control group. But

during the second half of the study, when both groups received

sibutramine, the results were more ambiguous. In months 6-12,

the group that continued to take sibutramine gained an average

of 0.8 kg, or roughly 2 pounds; the control group, which switched

from placebo to sibutramine, lost 1.3 kg, or roughly 3 pounds

(p. 1808). Both groups received behavioral therapy covering diet,

exercise, and mental health.

These results paint a murky picture of the effectiveness

of the medication: While initial data seemed promising,

the results after one year raised questions about whether

medicationinduced weight loss could be sustained over time.

As Berkowitz et al. (2003) advised, “Until more extensive

safety and efficacy data are available, . . . weight-loss

medications should be used only on an experimental basis

for adolescents” (p. 1811).

A study testing the effectiveness of orlistat in adolescents

showed similarly ambiguous results. The FDA approved orlistat

in 1999 but did not authorize it for adolescents until December

2003. Roche Laboratories (2003), maker of orlistat, released

results of a one-year study testing the drug on 539 obese

adolescents, aged 12-16. The drug, which promotes weight loss by

blocking fat absorption in the large intestine, showed some

effectiveness in adolescents: an average loss of 1.3 kg, or

roughly 3 pounds, for subjects taking orlistat for one year, as

opposed to an average gain of 0.67 kg, or 1.5 pounds, for the

control group (pp. 8-9). See Table 1.

Source: Diana Hacker (Boston: Bedford/St. Martin’s, 2006).

For a source with six or more authors, the first author’s name followed by “et al.” is used for the first and subsequent references.

Obesity in Children 8

Short-term studies of orlistat have shown slightly more

dramatic results. Researchers at the National Institute of Child

Health and Human Development tested 20 adolescents, aged

12-16, over a three-month period and found that orlistat,

combined with behavioral therapy, produced an average weight

loss of 4.4 kg, or 9.7 pounds (McDuffie et al., 2002, p. 646).

The study was not controlled against a placebo group; therefore,

the relative effectiveness of orlistat in this case remains

unclear.

Is Medication Safe for Children?

While modest weight loss has been documented for both

medications, each carries risks of certain side effects.

Sibutramine has been observed to increase blood pressure and

pulse rate. In 2002, a consumer group claimed that the

medication was related to the deaths of 19 people and filed a

petition with the Department of Health and Human Services to

ban the medication (Hilts, 2002). The sibutramine study by

Berkowitz et al. (2003) noted elevated blood pressure as a side

effect, and dosages had to be reduced or the medication

discontinued in 19 of the 43 subjects in the first six months

(p. 1809).

The main side effects associated with orlistat were

abdominal discomfort, oily spotting, fecal incontinence, and

nausea (Roche Laboratories, 2003, p. 13). More serious for

long-term health is the concern that orlistat, being a fat-

blocker, would affect absorption of fat-soluble vitamins, such

as vitamin D. However, the study found that this side effect

can be minimized or eliminated if patients take vitamin

Source: Diana Hacker (Boston: Bedford/St. Martin’s, 2006).

The writer develops the paper’s thesis.

Obesity in Children 9

supplements two hours before or after administration of orlistat

(p. 10). With close monitoring of patients taking the medication,

many of the risks can be reduced.

Is Medication the Best Solution?

The data on the safety and efficacy of pharmacological

treatments of childhood obesity raise the question of whether

medication is the best solution for the problem. The

treatments have clear costs for individual patients, including

unpleasant side effects, little information about long-term use,

and uncertainty that they will yield significant weight loss.

In purely financial terms, the drugs cost more than $3 a

day on average (Duenwald, 2004). In each of the clinical trials,

use of medication was accompanied by an expensive regime

of behavioral therapies, including counseling, nutritional

education, fitness advising, and monitoring. As journalist Greg

Critser (2003) noted in his book Fat Land, use of weight-loss

drugs is unlikely to have an effect without the proper “support

system”—one that includes doctors, facilities, time, and

money (p. 3). For some, this level of care is prohibitively

expensive.

A third complication is that the studies focused on

adolescents aged 12-16, but obesity can begin at a much younger

age. Little data exist to establish the safety or efficacy of

medication for treating very young children.

While the scientific data on the concrete effects of these

medications in children remain somewhat unclear, medication

is not the only avenue for addressing the crisis. Both medical

experts and policymakers recognize that solutions might come

Source: Diana Hacker (Boston: Bedford/St. Martin’s, 2006).

Brackets indicate a word not in the original source.

A quotation longer than 40 words is indented without quotation marks.

The writer inter- prets the evidence; she doesn’t just report it.

The tone of the conclusion is objective.

Obesity in Children 10

not only from a laboratory but also from policy, education, and

advocacy. Indeed, a handbook designed to educate doctors on

obesity recommended a notably nonmedical course of action,

calling for “major changes in some aspects of western culture”

(Hoppin & Taveras, 2004, Conclusion section, para. 1). Cultural

change may not be the typical realm of medical professionals,

but the handbook urged doctors to be proactive and “focus

[their] energy on public policies and interventions” (Conclusion

section, para. 1).

The solutions proposed by a number of advocacy groups

underscore this interest in political and cultural change. A report

by the Henry 3. Kaiser Family Foundation (2004) outlined trends

that may have contributed to the childhood obesity crisis,

including food advertising for children as well as

a reduction in physical education classes and after-school

athletic programs, an increase in the availability of sodas

and snacks in public schools, the growth in the number of

fast-food outlets . . . , and the increasing number of

highly processed high-calorie and high-fat grocery

products. (p. 1)

Addressing each of these areas requires more than a doctor

armed with a prescription pad; it requires a broad mobilization

not just of doctors and concerned parents but of educators,

food industry executives, advertisers, and media

representatives.

The barrage of possible approaches to combating childhood

obesity—from scientific research to political lobbying—

indicates both the severity and the complexity of the problem.

Source: Diana Hacker (Boston: Bedford/St. Martin’s, 2006).

Obesity in Children 11

While none of the medications currently available is a miracle

drug for curing the nation’s nine million obese children, research

has illuminated some of the underlying factors that affect

obesity and has shown the need for a comprehensive approach

to the problem that includes behavioral, medical, social, and

political change.

Source: Diana Hacker (Boston: Bedford/St. Martin’s, 2006).

List of references begins on a new page. Heading is centered.

List is alphabet- ized by authors’ last names. All authors’ names are inverted.

The first line of an entry is at the left margin; subsequent lines indent 1⁄2''.

Double-spacing is used throughout.

Obesity in Children 12

References

Berkowitz, R. I., Wadden, T. A., Tershakovec, A. M., & Cronquist,

J. L. (2003). Behavior therapy and sibutramine for the

treatment of adolescent obesity. Journal of the American

Medical Association, 289, 1805-1812.

Carmona, R. H. (2004, March 2). The growing epidemic of

childhood obesity. Testimony before the Subcommittee on

Competition, Foreign Commerce, and Infrastructure of

the U.S. Senate Committee on Commerce, Science, and

Transportation. Retrieved from http://www.hhs.gov/asl

/testify/t040302. html

Critser, G. (2003). Fat land. Boston, MA: Houghton Mifflin.

Duenwald, M. (2004, January 6). Slim pickings: Looking

beyond ephedra. The New York Times, p. F1. Retrieved from

http://nytimes.com/

Henry J. Kaiser Family Foundation. (2004, February). The role

of media in childhood obesity. Retrieved from http://www

.kff.org/entmedia/7030.cfm

Hilts, P. J. (2002, March 20). Petition asks for removal of diet

drug from market. The New York Times, p. A26. Retrieved

from http://nytimes.com/

Hoppin, A. G., & Taveras, E. M. (2004, June 25). Assessment

and management of childhood and adolescent obesity.

Clinical Update. Retrieved from http://www.medscape

.com/viewarticle/481633

McDuffie, J. R., Calis, K. A., Uwaifo, G. I., Sebring, N. G.,

Fallon, E. M., Hubbard, V. S., & Yanovski, J. A. (2002).

Three month tolerability of orlistat in adolescents with

Source: Diana Hacker (Boston: Bedford/St. Martin’s, 2006).

Obesity in Children 13

obesity-related comorbid conditions. Obesity Research,

10, 642-650.

Roche Laboratories. (2003, December). Xenical (orlistat)

capsules: Complete product information. Retrieved from

http://www.rocheusa.com/products/xenical/pi.pdf

Yanovski, S. Z., & Yanovski, J. A. (2002). Drug therapy: Obesity.

The New England Journal of Medicine, 346, 591-602.

Final Paper

Philosophy 2520 – 01 and 61S

Business Ethics

Please Note: This course will have a writing component. The final exam will consist of a 7–10-

page research paper focusing on ethical dilemmas in organizations. Your paper will be

due on May 6th, 2022, at 11:59pm.

Instructions

1. Choose one of the organizations listed in the case studies in Part 5 (case studies) of your

textbook or may select one of your choosing.

2. You are required to write your research paper utilizing APA (American Psychological

Association) format.

3. Your paper should contain the following information

a. Cover Page

b. Abstract

c. Content – Body of your paper

d. Conclusion

e. Reference Page

Scenario:

You are the new Compliance Officer at your organization. It is your responsibility to review the

current compliance policies, procedures, and practices of your organization. While reviewing and

auditing your organization, you discover there are several ethical dilemmas within the

organization. You are to write a proposal to your Board of Directors and the Executive Leadership

team within your organization. Your proposal should in include the following:

(1) Identify 2-3 ethical dilemmas within the organization.

(2) Discuss the dilemmas buy providing background information relating to each

dilemma.

(3) Describe what actions, processes, or compliant components that the organization used

to address the dilemma in the past

(4) Discuss rather the dilemma was rectified or is the organization still struggling with the

issue.

(5) As the new Compliance Officer, you are to create a compliance plan to address the

issues/behaviors. Discuss what techniques or tools you would implement to ensure

that these issues are addressed.

(6) Listed below are compliance models that you can use to assist you.

Sample Resources for your compliance plan.

Compliance Model

Elements of an effective compliance program

Compliance programs are not one-size-fits-all. Although you can follow the guidelines on how to create a compliance program and what to include, you’ll need to develop a plan that meets your company’s specific needs.

When it comes to building a compliance program, there’s no need to recreate the wheel.

The Affordable Care Act outlines seven key elements of an effective compliance program.

1. Establish and adopt written policies, procedures, and standards of conduct. Having clear written policies and procedures in place that describe compliance expectations fosters uniformity within your company.

2. Create program oversight. Determine who will oversee, monitor, and enforce the compliance program and serve as your go-to company “watchdog” with questions and concerns.

3. Provide staff training and education. Employees at every level need to understand your compliance program expectations and standards to be able to comply with them. Implement a training program that clearly communicates your company’s program requirements, with an annual refresher course that reminds employees of your code of conduct and incorporates any changes.

4. Establish two-way communication at all levels. Set forth the expectation that employees should proactively communicate in a timely manner, whether that means asking compliance questions, reporting issues, or addressing ethical concerns. Include a

way for employees to anonymously report compliance issues or fraudulent or illegal behavior without fear of retaliation.

5. Implement a monitoring and auditing system. You’ll need to measure the effectiveness of your corporate compliance program and identify risks. To accomplish this, develop a system of both internal and external monitoring, including formal audits.

6. Enforce consistent discipline. Develop a plan to enforce standards of conduct in a timely manner, outlining appropriate disciplinary measures for employees who fail to comply with program requirements.

7. Take corrective action. When you identify vulnerabilities or violations through monitoring and auditing, take timely, consistent action to correct the issue.

Keep in mind that this list is designed specifically for healthcare facilities. However, it serves as a solid guideline for any industry, touching on the key components of an effective compliance program. (Retrieved from https://www.powerdms.com/policy-learning-center/how-to-create- an-effective-compliance-program, 3/27/2022)

How you will be evaluated.

You will be evaluated on the following:

(1) Punctuation and grammar.

(2) APA format – Title Page, Abstract, running head, section headings, citations within the paper and reference page. (I have attached a sample APA style paper for your convenience.)

(3) Please note if you have references, you should have citations in your paper.

Make sure that you cite your sources in the body of your paper!

(4) Turn it in – I will be using Turn-it- in to ensure the academic integrity of your

paper. If your paper has a high percentage of plagiarism, it will result in a

failing grade. Cite your sources! Please review the university policy on

plagiarism.

(5) Please Note – Final Papers are due on the date specified. There will be No

Extensions or Exceptions.